From: Emerging agents and regimens for hepatocellular carcinoma
Trial | Lines | Arms | Clinicaltrials.gov identifier | Sponsor |
---|---|---|---|---|
IMbrave150 | First line | Atezolizumab + bevacizumab vs sorafenib | NCT03434379 | Roche |
 | First line | Tislelizumab vs sorafenib | NCT03412773 | BeiGene |
ZGDH3 | First line | Donafenib vs sorafenib | NCT02645981 | Zelgen |
HIMALAYA | First line | Durvalumab or durvalumab + tremelimumab vs sorafenib | NCT03298451 | AstraZeneca |
LEAP-002 | First line | Lenvatinib + pembrolizumab vs lenvatinib | NCT03713593 | MSD + Eisai |
COSMIC-312 | First line | Cabozantinib + atezolizumab vs sorafenib vs cabozantinib | NCT03755791 | Exelixis |
SHR-1210-III-310 | First line | Camrelizumab + apatinib vs sorafenib | NCT03764293 | Hengrui |
ORIENT-32 | First line | Sintilimab + IBI305 vs sorafenib | NCT03794440 | Innovent |
PHOCUS | First line | Pexa-Vec followed by sorafenib vs sorafenib | NCT02562755 | SillaJen |
KEYNOTE-394 | Second line | Pembrolizumab vs placebo in Asian pts. | NCT03062358 | MSD |
AHELP | Second line | Apatinib vs placebo | NCT02329860 | Hengrui |